Keywords: nice, backs, sanofi, acomplia, obesity, uk, national
NICE backs Sanofi's Acomplia for obesity
Article | 07 April 2008
The UK's National Institute for Health and Clinical Excellence (NICE) has recommended Sanofi-Aventis' Acomplia (rimonabant), within its licensed indications, as ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
